standard Doppler-echocardiographic parameters (including E/E' and left ventricular mass index (LVMI)). TTE was performed at baseline and at a predefined follow up visit (2 to 5 years post baseline). A significant increase in LAVI (LAVI progression) was defined as a change of > 3.5 ml/m 2 . BNP was measured at baseline and follow up visits. Hospitalisation for major adverse cardiovascular events (MACE) was identified from hospital discharges at least 2 years after the baseline visit. Multivariable-adjusted logistic regression was used to identify factors associated with LAVI progression and hospitalisation for MACE. Results There were 1238 patients enrolled in the service. Four hundred and forty seven (36.1%) of these were diabetic (mean age 64.7 years). The mean LAVI was 26.1 ml/m 2 in the diabetic group and 26.8 ml/m 2 in the non diabetic group (p = 0.5). LAVI progression was similar in both groups (31.6% DM vs 29.4% non DM, p = 0.44). Use of RAAS modifying therapy was higher in the diabetic group (56.3% vs 43.1%, p < 0.001). MACE occurred in 7.2% of the diabetic population and 3.2% of the non diabetic population (p = 0.001). MACE occurred in 6.4% of those with LAVI progression and in 3.7% of those without LAVI progression (p = 0.047). Baseline BNP was predictive of LAVI progression in the non diabetic group (OR 2.00, CI 1.04-3.86) but not in the diabetic group (OR 2.16, CI 0.86-5.42). Progression of BNP to an abnormal level at follow up was predictive of LAVI progression in the non diabetic group (OR 2.86, CI 1.62-5.07) but not in the diabetic group (OR 1.41, CI 0.64-3.09). Baseline BNP and progression of BNP to an abnormal level at follow up was predictive of MACE hospitalisation (OR 3.6, CI 1.54-8.41 and OR 3.93, CI 1.83-8.42 respectively). LAVI progression was associated with MACE on univariate analysis (OR 1.79, CI 1.00, 3.20) but not on multivariate analysis (OR 1.32, CI 0.71-2.44). Conclusions Preclinical diastolic dysfunction is prevalent among diabetics, progresses over time in a significant proportion and is potentially linked to clinical events. While NP identified the non diabetic at risk group, it did not predict risk in the diabetic group suggesting a handicap in NP function. This leaves an opportunity to intervene in the natural history of diabetic cardiomyopathy by modulating the NP system.
. BNP was measured at baseline and follow up visits. Hospitalisation for major adverse cardiovascular events (MACE) was identified from hospital discharges at least 2 years after the baseline visit. Multivariable-adjusted logistic regression was used to identify factors associated with LAVI progression and hospitalisation for MACE. Results There were 1238 patients enrolled in the service. Four hundred and forty seven (36.1%) of these were diabetic (mean age 64.7 years). The mean LAVI was 26.1 ml/m 2 in the diabetic group and 26.8 ml/m 2 in the non diabetic group (p = 0.5). LAVI progression was similar in both groups (31.6% DM vs 29.4% non DM, p = 0.44). Use of RAAS modifying therapy was higher in the diabetic group (56.3% vs 43.1%, p < 0.001). MACE occurred in 7.2% of the diabetic population and 3.2% of the non diabetic population (p = 0.001). MACE occurred in 6.4% of those with LAVI progression and in 3.7% of those without LAVI progression (p = 0.047). Baseline BNP was predictive of LAVI progression in the non diabetic group (OR 2.00, CI 1.04-3.86) but not in the diabetic group (OR 2.16, Objective Sudden cardiac arrest (SCA) is the most devastating outcome in hypertrophic cardiomyopathy (HCM). Presently, risk stratification is imperfect and underscores the need to identify novel markers for malignant disease. We evaluated repolarization features on the surface electrocardiograms (ECG) to identify potential risk factors for SCA. Methods Data was collected from 52 HCM patients who underwent implantable cardioverter defibrillator (ICD) implantation. Leads V2 and V5 from the ECG closest to the time of ICD implant were utilized for measuring the Tpeak-Tend interval (Tpe), QTc, Tpe/QTc, T-wave duration, and T-wave amplitude. The presence of the 5 traditional SCA-associated risk factors was assessed, as well as the HCM risk-SCD score. Results 16 (30%) patients experienced aborted cardiac arrest over 8.5±4.1 years, with 9 receiving an ICD shock and 7 receiving ATP. On univariate analysis, T-wave amplitude was associated with appropriate ICD therapy (HR per 0.1 mV 0.79, 95% CI 0.56-0.96, p=0.02). Aborted SCA was not associated with a greater mean QTc duration, Tpeak-Tend interval, T-wave duration, or Tpe/QT ratio. Multivariate analysis (adjusting for cardinal HCM SCA-risk factors) showed Twave amplitude in Lead V2 was an independent predictor of risk (adjusted HR per 0.1 mV 0.74, 95% CI 0.57-0.97, p =0.03). Addition of T-wave amplitude in Lead V2 to the traditional risk factors resulted in significant improvement in risk stratification (C-statistic from 0.65 to 0.75) but did not improve the performance of the HCM SCD-risk score. Conclusion T-wave amplitude is a novel marker of SCA in this high risk HCM population and may provide incremental predictive value to established risk factors. Further work is Abstract 60 Figure 1 Abstracts Heart 2017;103(Suppl 6):A1-A39 A35 Brugada syndrome (BrS) is associated with increased risk of cardiac arrest due to ventricular fibrillation and remains an important cause of sudden arrhythmic death syndrome (SADS). BrS is recognised by phenotypic electrocardiographic (ECG) patterns alongside specific clinical risk factors. The type 1 BrS pattern may either be spontaneous or concealed. Ajmaline, a class 1 C Sodium channel antagonist, is used to unmask the concealed pattern seen in BrS. We, retrospectively, reviewed all 231 patients that underwent ajamline provocation between 2011 and 2016. 59 (26%) patients had a concealed type 1 BrS pattern after ajmaline provocation. 105 patients with a family history of BrS were screened, in whom 38(36%) had a concealed pattern. Within this group 6 families had a history of overlapping Long QT Syndrome (LQTS). 61 patients screened had a family history of SADS. 5(8%) of these patients had a positive response. A further 12 patients were screened due to potential arrhythmic symptoms alongside borderline type 2 or 3 BrS patterns. 16 patients were referred after an aborted cardiac arrest (ACA), with 3(19%) of these patients having concealed BrS pattern after ajmaline provocation. 15(30%) of the patients with concealed BrS had an identifiable SCN5 A variant after serological genetic analysis. An A-ICD was inserted in 5(9%) patients with concealed BrS including all 3 patients with prior ACA and one patient with non-sustained monomorphic ventricular tachycardia (VT) detected via an implantable loop recorder (ILR). These patients remain free from VT and device-led therapy at present. An ILR was inserted in 9(17%) patients to further risk stratify patients with on-going potential arrhythmic symptoms. On ILR interrogation, 2 patients had episodes of non-sustained VT. Electrophysiological studies (EPS) were performed for diagnostic purposes, alongside ajmaline provocation, in 4(6.8%) of the patients with concealed BrS. 2 EPS were entirely negative. Ventricular fibrillation (VF) was induced in one study, and this patient currently awaits A-ICD insertion. The remaining EPS were negative. No cardiac adverse events occurred during or after ajmaline infusion. One patient had documented evidence of temporary cholestatic jaundice post administration, a recognised but rarely reported complication. All 59 patients with BrS remain free from sustained ventricular arrhythmias, ACA and sudden cardiac death (SCD) at this time.
In conclusion, ajmaline provocation is a safe and important diagnostic test for BrS. The ACA and ventricular arrhythmic event rate was low in our patient cohort. There was a 26% diagnostic yield in those patients referred as part of familial BrS screening, similar to that seen in other registries. The presence of a SCN5 A variant was seen in 30% of those with concealed BrS which is higher than previously published yields~20-25%. 19% of patients with a history of unexplained ACA had concealed BrS which is higher than that seen in the CASPER registry. Introduction Galectin-3 (Gal-3) is a pleiotropic lectin that is upregulated when monocytes differentiate into macrophages. It plays an important role in cell proliferation, angiogenesis and apoptosis. We aimed to determine the utility of Gal-3 as a marker of coronary plaque rupture and unstable plaque. Methods Consecutive patients presenting with chest pain to the emergency department of St James's Hospital, Dublin and those referred directly for angiography were enrolled between September 2014 to December 2015. Patients were divided into non-cardiac chest pain (NCCP), stable angina (SA) and acute coronary syndrome (ACS-unstable angina, NSTEMI and STEMI) based on clinical presentation, chest pain scoring tools (HEART, TIMI and GRACE score), electrocardiogram changes, troponin measurements and angiographic data. GENSINI and Syntax scores were used as measures of total plaque burden at angiography. Serum concentration of Gal-3 (0.3-10 ng/ml) was performed by ELISA (R and D Systems Inc). Results Patients (n=191), with NCCP (n=96), with SA (n=47) and with ACS (n=48) were enrolled. Mean age was 61± 11 years with 65% males. The mean concentration of Gal-3 in NCCP was 8.4± 0.3 ng/ml, 9 ± 2.3 ng/ml in SA and 9.8 ± 2.6 ng/ml in ACS (p =0.02). In patients with symptoms of chest pain within the preceding 12 hours (NCCP=50, SA= 27, ACS= 42) the mean concentration of Gal-3 was 10.1± 0.4 ng/ml for ACS, 9.1± 1.7 ng/ml in SA and 8.7± 0.3 ng/ ml in NCCP (p = 0.01). In patients with UA who were troponin negative and less likely to have undergone plaque rupture, Gal-3 was significantly elevated compared to both NCCP and SA at 10± 1.8 ng/ml (p<0.001). Table 1 highlights the correlations between Gal-3 and ACS patients. Conclusion Gal-3 was significantly elevated in ACS patients with plaque instability and rupture. In UA patients who were troponin negative and less likely to have undergone plaque rupture Gal-3 was significantly elevated. Gal-3 may be a marker of unstable coronary plaque where myocardial infarction has not occurred.
